Headquartered in Building B, Pudong Fiscal year ends December NASDAQ: ZLAB zailaboratory.com
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes medicines in oncology, immunology, neuroscience and infectious disease.
Its revenue comes mainly from net product sales in Greater China. Its commercial portfolio includes in-licensed products such as VYVGART/VYVGART Hytrulo (efgartigimod, partnered with argenx), NUZYRA, OPTUNE and KarXT, which launched in China in June 2026. It also earns a small amount of collaboration revenue.
The company is shifting toward internally developed global programs:
- **Zocilurtatug pelitecan (zoci, formerly ZL-1310):** a DLL3-targeting ADC in a registrational Phase 3 for second-line+ small cell lung cancer, with a first-line Phase 3 planned and a potential U.S. accelerated approval path in extrapulmonary neuroendocrine carcinomas.
- **ZL-1503:** a long-acting IL-13/IL-31Rα bispecific antibody for atopic dermatitis.
- **ZL-6201:** an LRRC15 ADC.
- **ZL-1311:** a MUC17/CD3 T-cell engager.
- **ZL-1222:** a PD-1/IL-12 program.
Regionally, it is developing efgartigimod for additional indications and elegrobart (a subcutaneous anti-IGF-1R) for thyroid eye disease in China. It also collaborates with Amgen and Boehringer Ingelheim on combinations of zoci with T-cell engagers. Updated
The loss came in 27% narrower than consensus, with revenue just shy of estimates. An 81.8% confirmed response rate for zocilurtatug pelitecan in first-line small-cell lung cancer is the pipeline driver, with management pointing to a first US BLA submission in 2027.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes medicines in oncology, immunology, neuroscience and infectious disease. Its revenue comes mainly from net product sales in Greater China.
The Wall Street consensus 12-month price target for ZLAB is $33.48.